Generics will hurt Glivec in China, docs say; Bayer evaluates Adempas in new indication;

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: AstraZeneca chief bristles at tying exec pay to Pfizer's spurned £55-per-share bid. Story | Follow @TracyStaton

@EricPFierce: FDA catches Wockhardt U.S. plant up to same tricks as banned Indian plants. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Valeant's Allergan bid gets hostile as Ackman makes a play for board control. Report | Follow @CarlyHFierce

@JustinHFierce: Norway's Vaccibody and Jersey's Phibro ink agreement for developing novel poultry vaccines to corner $1b market. Release | Follow @JustinHFierce

> Surveyed hematologists in China expect generics of Novartis' ($NVS) Glivec to significantly dent the drug's market share in chronic myeloid leukemia. Release

> Bayer is starting trials to investigate the use of Adempas in patients with symptomatic pulmonary hypertension or PH associated with idiopathic interstitial pneumonia. More

> Slovenian generics company Krka will delist 7.4% of its shares and buy back up to 10% more over the next three years. Report

> The EMA has accepted Vanda Pharmaceuticals' ($VNDA) marketing app for sleep disorder drug Hetlioz. More

> India's Aurobindo Pharma has won FDA approval to market a generic of AbbVie's ($ABBV) Depakote ER tablets in the U.S. Report

Medical Device News

@FierceMedDev: Merck will work with Sysmex to develop a colon cancer Dx that guides treatment for the drug Erbitux. Release | Follow @FierceMedDev

@VarunSaxena2: RT @AdvaMedUpdate: AdvaMed Opens China Office: official recognition will enhance AdvaMed's ability to partner w/ Chinese authorities. Release | Follow @VarunSaxena2

@MichaelGFierce: 'Quadrapeutics' works in preclinical study of hard-to-treat tumors. Story | Follow @MichaelGFierce

@EmilyWFierce: Devicemakers celebrate early regulatory wins despite 2013 setbacks. Report | Follow @EmilyWFierce

> Med tech incubator to assist Silicon Valley startups. Story

> OsteoSymbionics scores FDA clearance for craniofacial implant. More

> Digital health company Proteus bags $120M. Report

> Medtronic gets CE mark for its Duo insulin pump and glucose monitoring system. News

Biotech News

@FierceBiotech: Join @FierceBiotech's @JohnCFierce and a panel of experts at our Exec Breakfast in San Diego June 18th. More | Follow @FierceBiotech

@JohnCFierce: Love seeing $TEVA and $AZN provide huge peak sales projections on experimental drugs. Keep it coming. I will never forget. | Follow @JohnCFierce

@DamianFierce: "Marijn" rhymes with "Bahrain," not "Carmine," right? Release | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday: Omeros wins FDA blessing for eye treatment. Report | Follow @EmilyMFierce

> Prosensa gets an FDA green light for its once-failed DMD drug. News

> Teva buys into a blockbuster migraine drug rivalry with $825M Labrys buyout. More

> NPS throws ice water on $4B Shire rumor, but Wall Street keeps the faith. Article

> ASCO spotlight burns Puma shares. Item

> Sanofi CEO Viehbacher now calls beloved Boston biotech hub his home. Report

Biotech Research News

> Genetically engineered malaria parasite could expedite vaccine development. Article

> Alzheimer's compound gradually lowers amyloid in mice brains. Story

> Sangamo's gene editing tech fixes immune flaw in stem cell study. Article

> Biogen, Array strike preclinical autoimmune disease pact. Item

> Nektar cancer drug shrinks tumor growth in preclinical study. More

Pharma Manufacturing News

> FDA's OK for Boehringer Ingelheim plant gives it and Lilly hope on diabetes drug. Report

> Zydus recall flags another costly bottle mixup. Story

> Iran plant starts production of vet drugs but sets sights on human meds. More

> FDA catches Wockhardt U.S. plant using same spurious testing procedures as Indian plants. Article

> Alexion recalls Soliris for third time for particulate. Story

And Finally... Google Glass is entering the operating room. More (sub. req.)